Ambrx allies with Chinese firms to develop breast cancer drug

06/21/2013 | Pharmaceutical Business Review Online

Ambrx agreed to collaborate with Chinese firms Zhejiang Medicine and WuXi PharmaTech in the development and marketing of the antibody drug conjugate ARX788 for treatment of HER2-positive breast cancer. Zhejiang will shoulder the development costs and will get the right to market the drug in China. WuXi will provide development and production services for the toxin, antibody and ADC.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC